GENova Biotherapeutics signs collaboration agreement with Bridge Bioresearch

Thursday, September 17, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, NY, Sept. 14 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

The two biotechnology drug acquisition companies plan to leverage each others' scientific findings and industry contacts for mutual gain.

GENova's business solely focuses on cancer cures, while Bridge BioResearch is geared at acquiring drug targets for Obesity and Type 2 Diabetes. Through the collaboration agreement, the two companies will partner to share research results and their global contacts with research organizations and pharmaceutical companies. They will also examine their findings to gain insight into the links between their respective fields of oncology and obesity, as cancer and obesity are both maladies that can be blamed on lifestyle choices.

"By collaborating with Bridge BioResearch, we will gain access to their excellent network of high quality research labs and universities around the world, as well as their well-established distribution channels," says Aaron Whiteman, CEO for GENova. "We are confident that through this collaboration, we will gain access to the latest and greatest in developmental cancer drugs to perpetuate our acquisition pipeline, as well as secure reliable distribution channels for our out-licensing objectives."

"Furthermore, through this collaboration, we will exchange our scientific findings to gain insight into the links between obesity and cancer, as many findings suggest that one of the main factors in cancer development is lifestyle choices, including unhealthy diet," says Whiteman.

About Bridge Bioresearch

Bridge BioResearch is a drug discovery company with the sole corporate focus on Obesity, Type 2 Diabetes and related metabolic disorders. It has research cooperation agreements with leading Research and Development Services providers and bioscience research institutions and universities throughout Asia and Europe. The company uses a cost-efficient technology and patent acquisition strategy for proprietary intellectual property from identified companies, government institutions and universities, paid via milestone-dependent research collaborations and grants. To learn more about Bridge BioResearch, visit

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.

SOURCE GENova Biotherapeutics, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store